Details of Drug-Drug Interaction
| Drug General Information (ID: DDIZ4DCN76) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Triamterene | Drug Info | Tacrolimus | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Diuretics | Immunosuppressive Agents | |||||||
| Structure | |||||||||
| Mechanism of Triamterene-Tacrolimus Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of hyperkalemia Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Triamterene | Tacrolimus | |||||||
| Mechanism | Hyperkalemia | Hyperkalemia | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Hyperkalemia | ||||||||
| Factor Description | Hyperkalemia is a condition in which the level of potassium in the blood is higher than normal. While mild cases may not produce symptoms, severe hyperkalemia can lead to fatal arrhythmias if left untreated. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Potassium-sparing diuretics should generally be avoided during tacrolimus therapy. Patients treated with tacrolimus should have serum potassium levels and renal function monitored regularly, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat. | ||||||||